PM360

SEPTEMBER 21, 2023

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Clarivate

OCTOBER 25, 2023

While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. With 27.5%

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Technology

AUGUST 22, 2022

Softgels have now achieved strong recognition in the prescription, consumer health and supplements markets. If the doses can be combined, this decreases the burden on the patient and reduces prescription problems. billion by 2028, at a CAGR of 12.6%. This makes them ideal for patient groups such as children and seniors.

Prescription 52

Prescription Safety Patients Pharmaceutical 52

PM360

SEPTEMBER 21, 2023

This product would be a more potent prescription version than the OTCs, Casberg notes. This increases to 15 Part D drugs in 2026, as well as 15 Part B and D drugs in 2028, and a full 20 Part B and D drugs in 2029. The impact of the IRA’s price negotiations on payers is mixed, he noted.

Management 105

Management Manufacturing Sales Competition 105

Nixon Gwilt Law

MAY 26, 2023

The following Category III CPT codes are effective as of January 1, 2023, and are set to expire January 1, 2028, unless each code is individually modified to extend its expiration date or provide permanent payment. For information on how Nixon Gwilt helps DTx companies, click here.

Healthcare 119

Healthcare Healthcare Marketing Healthcare Provider 119

Clarivate

MAY 13, 2024

Many insurers use similar networks for Medicaid and exchange plans, so shifting to an exchange plan is less likely to cause a lapse in coverage or abandonment of prescription drugs or maintenance medications that control chronic conditions.

Insurance 52

Insurance Marketing Healthcare Healthcare 52

Pharmaceutical Representative Training

JANUARY 29, 2025

While biologics only account for 2% of overall prescriptions, they contribute to 37% of net drug spending [1]. The global biosimilars market is projected to grow beyond $68 billion by 2028, as more biologic patents are set to expire and generic manufacturers are expected to enter and evolve the market with their business practices. [4]

Marketing 52

Marketing Healthcare Healthcare Physicians 52

PM360

SEPTEMBER 28, 2022

In April 2022, we released an article describing proposed policies from the federal government that could impact prescription drug pricing. The facts: All Part D beneficiaries will pay $0 out of pocket for prescriptions in the catastrophic phase. On August 16, 2022, President Biden signed the Inflation Reduction Act (IRA) into law.

Manufacturing 97

Manufacturing Government Prescription Marketing 97

World of DTC Marketing

JULY 28, 2022

Nationwide, prescription drug spending last year is estimated to be $328 billion among all payers, including private insurance, Medicare Part D, and patients’ out-of-pocket expenses. Nearly 9 in 10 older adults take prescription medication. Still, the pharma industry is fighting hard to keep it off the table.

Pharma 256

Pharma Prescription Pharmaceutical Manufacturing 256

World of DTC Marketing

APRIL 7, 2022

By 2028, these costs are expected to climb to $6.2 While the media is focused on drug costs, which are a problem, only 12% of every healthcare dollar is spent on prescription drugs. In the Netherlands, only 12 percent of women said they had forgone care for cost reasons. THREAT 3: RISING HEALTHCARE COSTS. A study reported that U.S.

Healthcare 215

Healthcare Healthcare Food and Drug Administration Government 215

Clarivate

AUGUST 20, 2024

Moreover, the initial set of negotiated prices represents the first step of a process that eventually will reshape the pricing and reimbursement landscape for prescription drugs under Medicare as CMS gradually replaces private payers as the chief negotiating partner for some of the drug industry’s largest-selling treatments.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52